Ko­re­an start­up Curo­gen seeks glob­al ex­pan­sion, new fund­ing to back au­toim­mune drugs

Last month
Financing
Startups

Phase 3 or bust: Why Lil­ly won't run mid-stage can­cer tri­als

Last month
R&D

En­her­tu com­bo has the mak­ings of a new stan­dard in HER2-pos­i­tive breast can­cer

Last month
R&D
Pharma

Sanofi to snap up Blue­print Med­i­cines and mas­to­cy­to­sis drug Ay­vak­it for $9.1B

Last month
Deals
R&D

Kymera un­veils ‘ex­cep­tion­al’ Phase 1 da­ta for its Dupix­ent-in-a-pill pro­gram

Last month
R&D

Bris­tol My­ers bets $1.5B on BioN­Tech's PD-L1xVEGF from Bio­theus

Last month
Deals
China

Ve­ra posts pos­i­tive Phase 3 rare kid­ney dis­ease da­ta, but crowd­ed mar­ket looms

Last month
R&D
Pharma

In race with Merus, Bicara makes the case for two-year sur­vival da­ta

Last month
R&D

As­traZeneca de­tails its oral SERD 'switch­ing' reg­i­men as fea­si­bil­i­ty ques­tions re­main

Last month
R&D

As life-sav­ing check­point drugs move to ear­li­er can­cers, re­searchers de­bate how best to use them

Last month
R&D

Take­da, Pro­tag­o­nist un­veil ple­nary da­ta for po­ten­tial block­buster rare blood dis­ease drug

Last month
R&D

FDA ap­proves Mod­er­na’s next-gen Covid vac­cine, with lim­its on most healthy peo­ple

Last month
Pharma
FDA+

Im­mat­ics re­ports more ear­ly-stage da­ta for melanoma cell ther­a­py with piv­otal tri­al un­der­way

Last month
R&D
Cell/Gene Tx

En­her­tu ex­tends life by three months for some stom­ach can­cer pa­tients, study finds

Last month
R&D
Pharma

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

Last month
R&D
Pharma

Arv­inas, Pfiz­er's PRO­TAC in breast can­cer no bet­ter than oral SERDs

Last month
R&D

Pa­tient dies in Rock­et gene ther­a­py tri­al; Lil­ly’s $1B deal for a non-opi­oid pain biotech; A new dawn for ...

Last month
Weekly

Trump ad­min­is­tra­tion los­es bid to move ahead with HHS fir­ings, re­or­ga­ni­za­tion

Last month
Pharma
Law

As­traZeneca agrees to pay $51M to set­tle ‘pay-for-de­lay’ class ac­tion suit

Last month
Pharma
Law

HHS says it's pulled Covid shot guid­ance for healthy kids. The CDC vac­cine sched­ule shows oth­er­wise

Last month
Pharma
FDA+

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

Last month
R&D

Roche’s 96-week da­ta for mul­ti­ple scle­ro­sis drug; ZymeWorks claims $20M mile­stone

Last month
News Briefing

As a chal­leng­ing first half nears a close, bio­phar­ma un­cer­tain­ty per­sists

Last month
Financing
Deals

Q&A: Why for­mer Sen. Kyrsten Sine­ma is back­ing a psy­che­del­ic med­i­cine with po­ten­tial­ly more up­side, but more risk

Last month
People
R&D
First page Previous page 12131415161718 Next page Last page
A service from the Financial Times